$0.55 EPS Expected for CA, Inc. (CA); Bristol Myers Squibb Co (BMY) Has 1.03 Sentiment

December 31, 2017 - By Migdalia James

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $100.30 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.04 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Analysts expect CA, Inc. (NASDAQ:CA) to report $0.55 EPS on January, 23.They anticipate $0.02 EPS change or 3.51% from last quarter’s $0.57 EPS. CA’s profit would be $230.20 million giving it 15.13 P/E if the $0.55 EPS is correct. After having $0.57 EPS previously, CA, Inc.’s analysts see -3.51% EPS growth. The stock decreased 0.66% or $0.22 during the last trading session, reaching $33.28. About 1.54 million shares traded. CA, Inc. (NASDAQ:CA) has risen 0.22% since December 31, 2016 and is uptrending. It has underperformed by 16.48% the S&P500.

Since January 1, 0001, it had 1 insider buy, and 2 sales for $646,385 activity.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 22.87 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.

Terril Brothers Inc. holds 10.38% of its portfolio in Bristol-Myers Squibb Company for 508,489 shares. Blackhill Capital Inc owns 466,195 shares or 5.58% of their US portfolio. Moreover, Opus Point Partners Management Llc has 5.15% invested in the company for 90,000 shares. The North Carolina-based Westend Advisors Llc has invested 4.92% in the stock. Benchmark Capital Advisors, a New York-based fund reported 98,034 shares.

Ratings analysis reveals 33% of Bristol-Myers Squibb Co’s analysts are positive. Out of 3 Wall Street analysts rating Bristol-Myers Squibb Co, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $52.0 while the high is $70. The stock’s average target of $62.33 is 1.71% above today’s ($61.28) share price. BMY was included in 4 notes of analysts from November 18, 2015. The rating was upgraded by Jefferies on Monday, December 19 to “Buy”. The firm has “Hold” rating given on Friday, October 28 by Deutsche Bank. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, September 9 with “Equal Weight” rating.

The stock decreased 0.79% or $0.49 during the last trading session, reaching $61.28. About 3.95 million shares traded. Bristol-Myers Squibb Company (BMY) has declined 23.19% since December 31, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

CA, Inc. provides software and solutions that help organizations to plan, develop, manage, and secure applications and enterprise environments in the United States and internationally. The company has market cap of $13.93 billion. The firm operates through three divisions: Enterprise Solutions, Mainframe Solutions, and Services. It has a 19.24 P/E ratio. The Mainframe Solutions segment offers DevOps solutions and tools for development, testing, and deployment that support collaboration across the software development lifecycle and mobile to mainframe teams; activities intelligence and automation solutions; and security and compliance solutions.

Investors sentiment increased to 1.16 in Q3 2017. Its up 0.20, from 0.96 in 2017Q2. It is positive, as 33 investors sold CA, Inc. shares while 142 reduced holdings. 50 funds opened positions while 153 raised stakes. 277.99 million shares or 0.21% less from 278.58 million shares in 2017Q2 were reported. Lsv Asset holds 0.2% of its portfolio in CA, Inc. (NASDAQ:CA) for 3.66 million shares. Chevy Chase Trust Hldg holds 0.04% of its portfolio in CA, Inc. (NASDAQ:CA) for 275,564 shares. Jacobs Levy Equity stated it has 0.02% in CA, Inc. (NASDAQ:CA). Buckingham Capital Management Inc owns 26,697 shares. Proshare Limited Co reported 0.07% of its portfolio in CA, Inc. (NASDAQ:CA). Whittier Of Nevada reported 150 shares. 1.04M were reported by Thompson Siegel Walmsley Ltd Liability. 22,928 were reported by Security Bancshares Of So Dak. Regentatlantic Ltd Limited Liability Company has invested 0.96% in CA, Inc. (NASDAQ:CA). New Mexico Educational Retirement Board reported 29,127 shares or 0.05% of all its holdings. Engineers Gate Manager Lp invested in 16,825 shares. Royal Natl Bank Of Canada holds 0.01% of its portfolio in CA, Inc. (NASDAQ:CA) for 365,354 shares. Balyasny Asset holds 0% or 12,854 shares in its portfolio. Contravisory Invest Mgmt holds 78 shares or 0% of its portfolio. Cornerstone Advsrs Inc reported 785 shares or 0.02% of all its holdings.

Since August 7, 2017, it had 0 insider purchases, and 6 selling transactions for $9.33 million activity. Another trade for 71,235 shares valued at $2.38 million was made by GREGOIRE MICHAEL P on Monday, September 11. Shares for $5.37 million were sold by ELSTER ADAM on Monday, August 7. Shares for $546,792 were sold by Lamm Jacob on Monday, September 11. $606,994 worth of CA, Inc. (NASDAQ:CA) was sold by Sayed Ayman.

Among 16 analysts covering CA Technologies (NASDAQ:CA), 2 have Buy rating, 4 Sell and 10 Hold. Therefore 13% are positive. CA Technologies had 34 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of CA, Inc. (NASDAQ:CA) earned “Hold” rating by RBC Capital Markets on Sunday, August 20. The firm earned “Equal-Weight” rating on Thursday, October 26 by Barclays Capital. On Friday, July 7 the stock rating was maintained by Jefferies with “Buy”. As per Wednesday, January 11, the company rating was initiated by Wells Fargo. As per Thursday, April 21, the company rating was upgraded by Credit Suisse. The stock has “Sell” rating by Bernstein on Wednesday, June 28. Barclays Capital maintained CA, Inc. (NASDAQ:CA) on Thursday, August 3 with “Equal-Weight” rating. Cowen & Co maintained CA, Inc. (NASDAQ:CA) on Thursday, October 26 with “Sell” rating. The firm has “Hold” rating by TheStreet given on Friday, October 23. The firm has “Hold” rating by KeyBanc Capital Markets given on Thursday, October 26.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com